Jack B. Nielsen joined Vivo Capital as a Managing Director in 2017. Prior to joining Vivo, Jack worked within the Novo A/S organization and its venture activities since 2001 in several roles, most recently as a Senior Partner. From 2006 to 2012, Jack was employed as a Partner at Novo Ventures (US) Inc. in San Francisco, where he established Novo’s U.S. office. Jack currently serves as a member of the Board of Directors of Reata Pharmaceuticals Inc. He previously served on the board of directors of publicly-traded companies Akebia Therapeutics Inc., Merus, B.V and Apollo Endosurgery, Inc. He was also a member of the board of directors of a number of private companies including Alios Biopharma, Anokion, Kanyos Bio, NeoMend, Procept Biorobotics, ProteinSimple, Tobira Therapeutics, and Unchained Labs. From 1990 to 2001, Mr. Nielsen served various positions in Novo Nordisk A/S, ranging from R&D projects over large-scale production of enzymes to marketing and technical service in the textile areas. Jack received a M.Sc. in Chemical Engineering from the Technical University in Denmark and a Masters in Management of Technology from Center for Technology, Economics and Management; Technical University of Denmark.